Phase i and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 375-381

  Rudek, Michelle A ^b   New, Pamela ^a   Mikkelsen, Tom ^c   Phuphanich, Surasak ^d,g   Alavi, Jane B ^e   Nabors, Louis B ^f   Piantadosi, Steven ^b,g   Fisher, Joy D ^b   Grossman, Stuart A ^b,h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f University of Alabama at Birmingham   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anticonvulsants; COL 3; Gliomas; Pharmacokinetics

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; INCYCLINIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA; BRAIN HEMORRHAGE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOMA; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; MALE; MAXIMUM TOLERATED DOSE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; RECURRENT CANCER; STEADY STATE; TOXICITY TESTING;

ADULT; AGED; ANTICONVULSANTS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TETRACYCLINES; TISSUE DISTRIBUTION;

EID: 82955227413     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0602-9     Document Type: Article

References (26)

1. SA Grossman V Levin R Sawaya M Maor J Loeffler 1997 National comprehensive cancer network adult brain tumor practice guidelines Oncology 11 237 277 (Pubitemid 128529807)
2. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
3. PC Costello RF Del Maestro WG Stetler-Stevenson 1994 Gelatinase A expression in human malignant gliomas Ann N Y Acad Sci 732 450 452 7978836 10.1111/j.1749-6632.1994.tb24782.x 1:CAS:528:DyaK2MXjvFWqurc%3D
4. MH Friedberg MJ Glantz MS Klempner BF Cole G Perides 1998 Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis Cancer 82 923 930 9486583 10.1002/(SICI)1097-0142(19980301)82: 5<923::AID-CNCR18>3.0.CO;2-2 1:CAS:528:DyaK1cXhsVCru7s%3D (Pubitemid 28104173)
5. Z Kachra E Beaulieu L Delbecchi N Mousseau F Berthelet R Moumdjian R Del Maestro R Beliveau 1999 Expression of matrix metalloproteinases and their inhibitors in human brain tumors Clin Exp Metastasis 17 555 566 10845554 10.1023/A:1006760632766 1:CAS:528:DC%2BD3cXksl2mu7k%3D (Pubitemid 30337129)
6. RE Sawaya M Yamamoto ZL Gokaslan SW Wang S Mohanam GN Fuller IE McCutcheon WG Stetler-Stevenson GL Nicolson JS Rao 1996 Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo Clin Exp Metastasis 14 35 42 8521615 10.1007/BF00157684 1:STN:280:DyaK287gs1Cnsg%3D%3D (Pubitemid 26009753)
7. M Wang T Wang S Liu D Yoshida A Teramoto 2003 The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades Brain Tumor Pathol 20 65 72 14756443 10.1007/BF02483449 (Pubitemid 38146273)
8. KV Lu KA Jong AK Rajasekaran TF Cloughesy PS Mischel 2004 Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line Lab Invest 84 8 20 14631378 10.1038/labinvest.3700003 1:CAS:528:DC%2BD2cXmtFyrs74%3D (Pubitemid 41656430)
9. JC Tonn S Kerkau A Hanke H Bouterfa JG Mueller S Wagner GH Vince K Roosen 1999 Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro Int J Cancer 80 764 772 10048980 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0. CO;2-J 1:CAS:528:DyaK1MXhtlSgtrs%3D (Pubitemid 29066291)
10. H Nakabayashi T Yawata K Shimizu 2010 Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells BMC Cancer 10 339 20587068 10.1186/1471-2407-10-339
11. LM Golub NS Ramamurthy TF McNamara RA Greenwald BR Rifkin 1991 Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs Crit Rev Oral Biol Med 2 297 321 1654139 1:STN:280:DyaK3MzntVWqtA%3D%3D
12. M Hidalgo SG Eckhardt 2001 Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 178 193 11158186 10.1093/jnci/93.3.178 1:CAS:528:DC%2BD3MXhtlKiurw%3D (Pubitemid 32166488)
13. MA Rudek WD Figg V Dyer W Dahut ML Turner SM Steinberg DJ Liewehr DR Kohler JM Pluda E Reed 2001 Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer J Clin Oncol 19 584 592 11208854 1:CAS:528:DC%2BD3MXhtVektLY%3D (Pubitemid 32112874)
14. S Syed C Takimoto M Hidalgo J Rizzo JG Kuhn LA Hammond G Schwartz A Tolcher A Patnaik SG Eckhardt EK Rowinsky 2004 A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties Clin Cancer Res 10 6512 6521 15475438 10.1158/1078-0432.CCR-04-0804 1:CAS:528:DC%2BD2cXot1Oiur4%3D (Pubitemid 39359234)
15. M Cianfrocca TP Cooley JY Lee MA Rudek DT Scadden L Ratner JM Pluda WD Figg SE Krown BJ Dezube 2002 Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study J Clin Oncol 20 153 159 11773164 10.1200/JCO.20.1.153 1:CAS:528:DC%2BD38XnsFertw%3D%3D (Pubitemid 34032606)
16. QS Chu B Forouzesh S Syed M Mita G Schwartz J Cooper J Curtright EK Rowinsky 2007 A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas Invest New Drugs 25 359 367 17237909 10.1007/s10637-006-9031-6 1:CAS:528:DC%2BD2sXmsFKjtrk%3D (Pubitemid 46944843)
17. JV Ghate ML Turner MA Rudek WD Figg W Dahut V Dyer JM Pluda E Reed 2001 Drug-induced lupus associated with COL-3: report of 3 cases Arch Dermatol 137 471 474 11295928 1:STN:280:DC%2BD3M3jslGltw%3D%3D (Pubitemid 32319843)
18. MR Gilbert JG Supko T Batchelor G Lesser JD Fisher S Piantadosi S Grossman 2003 Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma Clin Cancer Res 9 2940 2949 12912940 1:CAS:528:DC%2BD3sXmtF2iu7Y%3D (Pubitemid 37006309)
19. MA Rudek C Hartke Y Zabelina M Zhao P New SD Baker 2005 A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection J Pharm Biomed Anal 37 751 756 15797797 10.1016/j.jpba.2004.10.052 1:CAS:528:DC%2BD2MXjt1ajsLk%3D (Pubitemid 40417749)
20. MA Rudek J Venitz Y Ando E Reed JM Pluda WD Figg 2003 Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies J Clin Pharmacol 43 1124 1135 14517195 10.1177/0091270003256675 1:CAS:528:DC%2BD3sXot1Wjs74%3D (Pubitemid 37174444)
21. J Li S Zhou H Huynh E Chan 2005 Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline Pharm Res 22 397 404 15835745 10.1007/s11095-004-1877-8 (Pubitemid 40558498)
22. J Li H Huynh E Chan 2002 Evidence for dissolution rate-limited absorption of COL-3, a Matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration Pharm Res 19 1655 1662 12458671 10.1023/A:1020901328583 1:CAS:528:DC%2BD38XotV2hurw%3D (Pubitemid 35305517)
23. GD Anderson 1998 A mechanistic approach to antiepileptic drug interactions Ann Pharmacother 32 554 563 9606477 10.1345/aph.17332 1:CAS:528:DyaK1cXjsVOksrY%3D (Pubitemid 28232761)
24. L Sutherland T Ebner B Burchell 1993 The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs Biochem Pharmacol 45 295 301 8435089 10.1016/0006-2952(93) 90064-4 1:CAS:528:DyaK3sXhtl2hsrc%3D (Pubitemid 23042627)
25. MD Groves VK Puduvalli CA Conrad MR Gilbert WK Yung K Jaeckle V Liu KR Hess KD Aldape VA Levin 2006 Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status J Neurooncol 80 83 90 16639492 10.1007/s11060-006-9160-y 1:CAS:528:DC%2BD28XhtlSjsbzE (Pubitemid 44473266)
26. MD Groves VK Puduvalli KR Hess KA Jaeckle P Peterson WK Yung VA Levin 2002 Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20 1383 1388 11870183 10.1200/JCO.20.5.1383 1:CAS:528:DC%2BD38XisVWmu7g%3D (Pubitemid 34177446)